The Right to Design Babies? Human Rights and Bioethics
By Roberto Andorno and Alicia Ely Yamin,
Open Global Rights
| 01. 08. 2019
The gene-editing scandal that made headlines in late November, with researcher He Jiankui claiming to have created twin girls whose DNA he had altered at the embryo stage, heightened global awareness of a consequential and close-at-hand decision about how to use and regulate powerful new human biotechnologies. This controversy about whether altering the genes of future children and generations should be permissible had already re-emerged in 2015, after the gene editing tool CRISPR-Cas9 was first used to change the DNA of human embryos in the laboratory. Oddly, the current conversation often ignores a robust set of deliberations about “heritable genetic modification” that took place during the 1990s, as the mapping of the human genome got underway.
By the end of the 1990s, most bioethicists, governments and international organizations had agreed that it would be wrong to introduce inheritable alterations into the genome of human beings. This was regarded as a red line that should never be crossed, based on serious concern for the integrity of future generations. There was a concern about the risk of unintended consequences and potentially...
Related Articles
By Mike McIntire, The New York Times | 01.24.2026
Genetic researchers were seeking children for an ambitious, federally funded project to track brain development — a study that they told families could yield invaluable discoveries about DNA’s impact on behavior and disease.
They also promised that the children’s sensitive...
By Arthur Lazarus, MedPage Today | 01.23.2026
A growing body of contemporary research and reporting exposes how old ideas can find new life when repurposed within modern systems of medicine, technology, and public policy. Over the last decade, several trends have converged:
- The rise of polygenic scoring...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...